Summary
AbbVie Inc. (ABBV) filed an 8-K on April 29, 2022, primarily to report its first-quarter 2022 financial results. The company issued a press release on April 29, 2022, detailing its performance for the quarter ended March 31, 2022. This filing serves as the official notification and provides investors with access to the company's latest financial performance data. The core of this 8-K pertains to the information contained within the furnished press release (Exhibit 99.1). Investors should refer to this press release for specific details on revenue, earnings, operational performance, and any forward-looking guidance provided by AbbVie for the first quarter of 2022.
Key Highlights
- 1AbbVie announced its first-quarter 2022 financial results via a press release on April 29, 2022.
- 2The 8-K filing incorporates by reference the full press release detailing the financial performance.
- 3Investors can find detailed information on the company's operations and financial condition for the quarter ended March 31, 2022, within the furnished press release.
- 4The filing includes Exhibit 99.1 (the press release) and Exhibit 104 (Inline XBRL cover page).
- 5This report is an update on AbbVie's financial performance and does not appear to contain significant new business developments or material changes outside of its quarterly results.
- 6The furnished press release is the primary source for understanding AbbVie's Q1 2022 performance and outlook.